{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:14:59Z","timestamp":1789600499735,"version":"build-2803163510"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Preliminary studies indicated that enhanced plasma levels of lipoprotein(a) [lp(a)] might link with the risk of calcific aortic valve disease (CAVD), but the clinical association between them remained inconclusive. This systematic review and meta-analysis were aimed to determine this association.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We comprehensively searched PubMed, Embase, Web of Science, and Scopus databases for studies reporting the incidence of CAVD and their plasma lp(a) concentrations. Pooled risk ratio (RR) and 95% confidence interval (95% CI) were calculated to evaluate the effect of lp(a) on CAVD using the random-effects model. Subgroup analyses by study types, countries, and the level of adjustment were also conducted. Funnel plots, Egger's test and Begg's test were conducted to evaluate the publication bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight eligible studies with 52,931 participants were included in this systematic review and meta-analysis. Of these, four were cohort studies and four were case-control studies. Five studies were rated as high quality, three as moderate quality. The pooled results showed that plasma lp(a) levels \u226550 mg\/dL were associated with a 1.76-fold increased risk of CAVD (RR, 1.76; 95% CI, 1.47\u20132.11), but lp(a) levels \u226530 mg\/dL were not observed to be significantly related with CAVD (RR, 1.28; 95% CI, 0.98\u20131.68). We performed subgroup analyses by study type, the RRs of cohort studies revealed lp(a) levels \u226550 mg\/dL and lp(a) levels \u226530 mg\/dL have positive association with CAVD (RR, 1.70; 95% CI, 1.39\u20132.07; RR 1.38; 95% CI, 1.19\u20131.61).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High plasma lp(a) levels (\u226550 mg\/dL) are significantly associated with increased risk of CAVD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2022.877140","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T06:50:29Z","timestamp":1650869429000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Association Between Lipoprotein(a) and Calcific Aortic Valve Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.3389","volume":"9","author":[{"given":"Qiyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixi","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runmin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqing","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1161\/circulationaha.119.043391","article-title":"Global, regional, and national burden of calcific aortic valve and degenerative mitral valve diseases, 1990-2017","volume":"141","author":"Yadgir","year":"2020","journal-title":"Circulation."},{"key":"B2","doi-asserted-by":"publisher","first-page":"16006","DOI":"10.1038\/nrdp.2016.6","article-title":"Calcific aortic stenosis","volume":"2","author":"Lindman","year":"2016","journal-title":"Nat Rev Dis Prim."},{"key":"B3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11886-018-0968-9","article-title":"Calcific aortic valve disease: a developmental biology perspective","volume":"20","author":"Dutta","year":"2018","journal-title":"Curr Cardiol Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1161\/cir.0000000000000932","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/eurheartj\/ehab757","article-title":"Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy","volume":"43","author":"Kraler","year":"2022","journal-title":"Eur Heart J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/ehjcvp\/pvw027","article-title":"Is the use of renin-angiotensin system inhibitors in patients with aortic valve stenosis safe and of prognostic benefit? A systematic review and meta-analysis","volume":"3","author":"Andersson","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"B7","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1161\/circulationaha.109.900027","article-title":"Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial","volume":"121","author":"Chan","year":"2010","journal-title":"Circulation."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rosseb\u00f8","year":"2008","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.amjcard.2008.04.060","article-title":"Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg)","volume":"102","author":"Dichtl","year":"2008","journal-title":"Am J Cardiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ihj.2019.03.004","article-title":"Lipoprotein(a): an independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction","volume":"71","author":"Enas","year":"2019","journal-title":"Indian Heart J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.atherosclerosis.2018.03.025","article-title":"Pathological significance of lipoprotein(a) in aortic valve stenosis","volume":"272","author":"Yu","year":"2018","journal-title":"Atherosclerosis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1161\/circulationaha.116.026103","article-title":"A replicated, genome-wide significant association of aortic stenosis with a genetic variant for lipoprotein(a): meta-analysis of published and novel data","volume":"135","author":"Cairns","year":"2017","journal-title":"Circulation."},{"key":"B16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/circgenetics.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e007160","DOI":"10.1161\/jaha.117.007160","article-title":"Lipoprotein(a) and the apolipoprotein B\/A1 ratio independently associate with surgery for aortic stenosis only in patients with concomitant coronary artery disease","volume":"6","author":"Ljungberg","year":"2017","journal-title":"J Am Heart Assoc."},{"key":"B19","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.amjcard.2018.04.046","article-title":"Comparison of lipoprotein(a)-levels in patients \u226570 years of age with versus without aortic valve stenosis","volume":"122","author":"Mahabadi","year":"2018","journal-title":"Am J Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA."},{"key":"B22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1161\/atvbaha.114.304785","article-title":"Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis","volume":"35","author":"Guan","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.cjca.2016.07.510","article-title":"2016 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3969\/j.issn.1000-3614.2021.12.003","article-title":"Expert statement on the relationship between lipoprotein(a) and cardiovascular disease risk and clinical management","volume":"36","author":"Li","year":"2021","journal-title":"Chin Circu J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1161\/atvbaha.115.306683","article-title":"Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in white and black individuals: the multi-ethnic study of atherosclerosis","volume":"36","author":"Cao","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e013020","DOI":"10.1161\/jaha.119.013020","article-title":"apoB\/apoA-I ratio and Lp(a) associations with aortic valve stenosis incidence: insights from the EPIC-Norfolk prospective population study","volume":"8","author":"Zheng","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1161\/atvbaha.116.308615","article-title":"Biomarkers of Calcific Aortic Valve Disease","volume":"37","author":"Small","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"12710","DOI":"10.18632\/aging.202942","article-title":"Changing epidemiology of calcific aortic valve disease: 30-year trends of incidence, prevalence, and deaths across 204 countries and territories","volume":"13","author":"Yi","year":"2021","journal-title":"Aging."},{"key":"B32","doi-asserted-by":"publisher","first-page":"f7450","DOI":"10.1136\/bmj.f7450","article-title":"Converting an odds ratio to a range of plausible relative risks for better communication of research findings","volume":"348","author":"Grant","year":"2014","journal-title":"BMJ."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods."},{"key":"B35","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1161\/atvbaha.116.308271","article-title":"Estimating the population impact of lp(a) lowering on the incidence of myocardial infarction and aortic stenosis-brief report","volume":"36","author":"Afshar","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/s0195-668x(02)00385-8","article-title":"Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis","volume":"24","author":"Glader","year":"2003","journal-title":"Eur Heart J."},{"key":"B38","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/joim.12335","article-title":"Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia","volume":"278","author":"Vongpromek","year":"2015","journal-title":"J Intern Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1177\/0003319716688415","article-title":"The prevalence of lipoprotein(a) measurement and degree of elevation among 2710 patients with calcific aortic valve stenosis in an academic echocardiography laboratory setting","volume":"68","author":"Wilkinson","year":"2017","journal-title":"Angiology."},{"key":"B40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2020.09.010","article-title":"Lipoprotein (a) and aortic valve calcium in South Asians compared to other race\/ethnic groups","volume":"313","author":"Makshood","year":"2020","journal-title":"Atherosclerosis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/joim.12519","article-title":"Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease","volume":"280","author":"Nsaibia","year":"2016","journal-title":"J Intern Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jcmg.2011.12.023","article-title":"Aortic valve calcium independently predicts coronary and cardiovascular events in a primary prevention population","volume":"5","author":"Owens","year":"2012","journal-title":"JACC Cardiovasc Imaging."},{"key":"B43","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/hrt.2010.198853","article-title":"Measurement of aortic valve calcification using multislice computed tomography: correlation with haemodynamic severity of aortic stenosis and clinical implication for patients with low ejection fraction","volume":"97","author":"Cueff","year":"2011","journal-title":"Heart."},{"key":"B44","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2010.08.070","article-title":"Combined presence of aortic valve calcification and mitral annular calcification as a marker of the extent and vulnerable characteristics of coronary artery plaque assessed by 64-multidetector computed tomography","volume":"213","author":"Utsunomiya","year":"2010","journal-title":"Atherosclerosis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.amjcard.2010.08.019","article-title":"Relation of aortic valve calcium detected by cardiac computed tomography to all-cause mortality","volume":"106","author":"Blaha","year":"2010","journal-title":"Am J Cardiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4103\/0019-5154.177773","article-title":"Methodology Series Module 2: Case-control Studies","volume":"61","author":"Setia","year":"2016","journal-title":"Indian J Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jss.2013.05.001","article-title":"Ox-LDL induces PiT-1 expression in human aortic valve interstitial cells","volume":"184","author":"Nadlonek","year":"2013","journal-title":"J Surg Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/j.1365-2559.2012.04265.x","article-title":"Amyloid substance within stenotic aortic valves promotes mineralization","volume":"61","author":"Audet","year":"2012","journal-title":"Histopathology."},{"key":"B49","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.atherosclerosis.2014.11.026","article-title":"Early aortic valve inflammation precedes calcification: a longitudinal FDG-PET\/CT study","volume":"238","author":"Abdelbaky","year":"2015","journal-title":"Atherosclerosis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/medicina55080416","article-title":"HDL-C role in acquired aortic valve stenosis patients and its relationship with oxidative stress","volume":"55","author":"Hofmanis","year":"2019","journal-title":"Medicina."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1093\/eurheartj\/ehaa070","article-title":"Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study","volume":"41","author":"Nazarzadeh","year":"2020","journal-title":"Eur Heart J."},{"key":"B52","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.atherosclerosis.2016.01.023","article-title":"The effect of statins on valve function and calcification in aortic stenosis: a meta-analysis","volume":"246","author":"Zhao","year":"2016","journal-title":"Atherosclerosis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2459\/JCM.0b013e3283587267","article-title":"Statin use for nonrheumatic calcific aortic valve stenosis: a review with meta-analysis","volume":"14","author":"De Vecchis","year":"2013","journal-title":"J Cardiovasc Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.pcad.2020.06.002","article-title":"Lipoprotein(a) and calcific aortic valve stenosis: a systematic review","volume":"63","author":"Guddeti","year":"2020","journal-title":"Prog Cardiovasc Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein(a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1021\/bi00767a015","article-title":"Protein and carbohydrate composition of Lp(a)lipoprotein from human plasma","volume":"11","author":"Ehnholm","year":"1972","journal-title":"Biochemistry."},{"key":"B57","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1194\/jlr.R051870","article-title":"Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis","volume":"57","author":"Thanassoulis","year":"2016","journal-title":"J Lipid Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1161\/01.res.78.4.615","article-title":"Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo","volume":"78","author":"Nielsen","year":"1996","journal-title":"Circ Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/hco.0000000000000901","article-title":"The current landscape of lipoprotein(a) in calcific aortic valvular disease","volume":"36","author":"Hsieh","year":"2021","journal-title":"Curr Opin Cardiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/atvbaha.116.308761","article-title":"Oxidized phospholipids and risk of calcific aortic valve disease: the Copenhagen general population study","volume":"37","author":"Kamstrup","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.tcm.2020.06.001","article-title":"Lipoprotein(a): expanding our knowledge of aortic valve narrowing","volume":"31","author":"Youssef","year":"2021","journal-title":"Trends Cardiovasc Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10557-008-6133-8","article-title":"Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2)","volume":"23","author":"Stafforini","year":"2009","journal-title":"Cardiovasc Drugs Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2010.04.005","article-title":"Lyso-phosphatidylcholine induces osteogenic gene expression and phenotype in vascular smooth muscle cells","volume":"211","author":"Vickers","year":"2010","journal-title":"Atherosclerosis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/circulationaha.115.016757","article-title":"Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve","volume":"132","author":"Bouchareb","year":"2015","journal-title":"Circulation."},{"key":"B66","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jacbts.2017.03.015","article-title":"Lipoprotein(a) induces human aortic valve interstitial cell calcification","volume":"2","author":"Yu","year":"2017","journal-title":"JACC Basic Transl Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1093\/eurjpc\/zwaa063","article-title":"Lipoprotein(a) and cardiovascular disease: prediction, attributable1 risk fraction, and estimating benefits from novel interventions","volume":"28","author":"Welsh","year":"2022","journal-title":"Eur J Prev Cardiol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J."},{"key":"B70","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1161\/atvbaha.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/s0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.877140\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T06:50:32Z","timestamp":1650869432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.877140\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,25]]},"references-count":71,"alternative-id":["10.3389\/fcvm.2022.877140"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.877140","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,25]]},"article-number":"877140"}}